These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 15203725

  • 1. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study.
    Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE.
    Pathology; 2004 Jun; 36(3):221-9. PubMed ID: 15203725
    [Abstract] [Full Text] [Related]

  • 2. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003 Jun; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
    Idvall I, Ringberg A, Anderson H, Akerman M, Fernö M.
    Breast; 2005 Aug; 14(4):290-7. PubMed ID: 16085235
    [Abstract] [Full Text] [Related]

  • 9. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ.
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Bilateral ductal carcinoma in situ of the breast: independent events or bilateral disease?].
    André G, Tunon-de-Lara C, Macgrogan G, Laharie-Mineur H, Bussieres JE, Valentin F, Barreau B, Dilhuydy MH, Dilhuydy JM, Mauriac L, Debled M, Durand M, Mathoulin S, Avril A.
    J Gynecol Obstet Biol Reprod (Paris); 2007 May; 36(3):260-6. PubMed ID: 17376610
    [Abstract] [Full Text] [Related]

  • 16. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    EORTC Breast Cancer Cooperative GroupDepartment of Radiation Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands. n.bijker@nki.nl, EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ.
    J Clin Oncol; 2006 Jul 20; 24(21):3381-7. PubMed ID: 16801628
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
    Mokbel K.
    Int J Fertil Womens Med; 2003 Jul 20; 48(5):217-25. PubMed ID: 14626378
    [Abstract] [Full Text] [Related]

  • 18. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M, Melville KA, Barnes PJ, MacIntosh RF, Caines JS, Porter GA.
    J Surg Oncol; 2005 May 01; 90(2):71-6. PubMed ID: 15844190
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
    Denoux Y, Marnay J, Crouet H, Boute V, Delozier T, Vie B, Chasle J.
    Bull Cancer; 2001 Apr 01; 88(4):419-25. PubMed ID: 11371378
    [Abstract] [Full Text] [Related]

  • 20. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.
    Cancer; 2006 Jan 01; 106(1):42-50. PubMed ID: 16333852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.